Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 1/20 | 0.42 |
| ▸ | PLAT | P00750 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | MMP12 | P39900 | 1/20 | 0.35 |
| ▸ | ANPEP | P15144 | 2/20 | 0.35 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.34 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2340454 | 1.00 | PLG (0.42) | PLGPLATLMNAKMT2ACACNA1H | |
| SCHEMBL2340457 | 1.00 | PLG (0.42) | PLGPLATLMNAKMT2ACACNA1H | |
| SCHEMBL22571032 | 1.00 | PLG (0.42) | PLGPLATLMNAKMT2ACACNA1H | |
| SCHEMBL680677 | 0.89 | PLG (0.50) | PLGPLATLMNAKMT2ACACNA1H | |
| SCHEMBL680676 | 0.89 | PLG (0.50) | PLGPLATLMNAKMT2ACACNA1H | |
| Tranexamic Acid SCHEMBL2569232 | 0.81 | PLG (0.67) | PLGPLATLMNAKMT2ATDP1 | |
| SCHEMBL48633 | 0.80 | — | — | |
| SCHEMBL13165688 | 0.80 | TDP1 (0.58) | CACNA1HTDP1SMN1; SMN2ALDH1A1EPHX1 | |
| SCHEMBL4861735 | 0.79 | TDP1 (0.45) | KMT2ACACNA1HTDP1SMN1; SMN2ALDH1A1 | |
| SCHEMBL4861746 | 0.79 | TDP1 (0.45) | KMT2ACACNA1HTDP1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0933993-B1 | SUBSTITUTED CYCLOPENTANE COMPOUNDS USEFUL AS NEURAMINIDASE INHIBITORS | BIOCRYST PHARM INC (US) | 2006-04-05 | — | — | EP | claimed |
| EP-0933993-A4 | SUBSTITUTED CYCLOPENTANE COMPOUNDS USEFUL AS NEURAMINIDASE INHIBITORS | BIOCRYST PHARM INC (US) | 2004-09-08 | — | — | EP | claimed |
| US-6410594-B1 | VIRICIDES | BIOCRYST PHARMACEUTICALS, INC. | 2002-06-25 | — | — | US | claimed |
| EP-0933993-A1 | SUBSTITUTED CYCLOPENTANE COMPOUNDS USEFUL AS NEURAMINIDASE INHIBITORS | BIOCRYST PHARMACEUTICALS INC. (US) | 1999-08-11 | — | — | EP | claimed |
| WO-1997047194-A1 | SUBSTITUTED CYCLOPENTANE COMPOUNDS USEFUL AS NEURAMINIDASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 1997-12-18 | — | — | WO | claimed |
| EP-3320921-B1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | ALA WAI PHARMA INC (US) | 2022-01-05 | — | — | EP | disclosed |
| US-20180153817-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | ALA WAI PHARMA, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| EP-3320921-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | Ala Wai Pharma, Inc. (US) | 2018-05-16 | — | — | EP | disclosed |
| EP-2217216-B1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | ALA WAI PHARMA INC (US) | 2017-09-27 | — | — | EP | disclosed |
| US-20170157059-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | ALA WAI PHARMA, INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-9579383-B2 | Formulations for enhanced bioavailability of orally administered polar agents | ALA WAI PHARMA, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20140072627-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | ALA WAI PHARMA, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20110206764-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | UNIVERSITY OF HAWAII | 2011-08-25 | — | — | US | disclosed |
| EP-2217216-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | Scolr Pharma, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009061805-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | SCOLR PHARMA, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
| EP-0933993-B1 | SUBSTITUTED CYCLOPENTANE COMPOUNDS USEFUL AS NEURAMINIDASE INHIBITORS | BIOCRYST PHARM INC (US) | 2006-04-05 | — | — | EP | disclosed |
| EP-0933993-A4 | SUBSTITUTED CYCLOPENTANE COMPOUNDS USEFUL AS NEURAMINIDASE INHIBITORS | BIOCRYST PHARM INC (US) | 2004-09-08 | — | — | EP | disclosed |
| US-6410594-B1 | VIRICIDES | BIOCRYST PHARMACEUTICALS, INC. | 2002-06-25 | — | — | US | disclosed |
| EP-0933993-A1 | SUBSTITUTED CYCLOPENTANE COMPOUNDS USEFUL AS NEURAMINIDASE INHIBITORS | BIOCRYST PHARMACEUTICALS INC. (US) | 1999-08-11 | — | — | EP | disclosed |
| WO-1997047194-A1 | SUBSTITUTED CYCLOPENTANE COMPOUNDS USEFUL AS NEURAMINIDASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 1997-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157059-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | SLC35A1, SLC29A2, NEU2 | PLG 1107/4885PLAT 1155/4885LMNA 774/4885 |
| US-20110206764-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | SLC35A1, SLC29A2, NEU2 | PLG 1107/4885PLAT 1155/4885LMNA 774/4885 |
| US-20180153817-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | SLC35A1, SLC29A2, NEU2 | PLG 1107/4885PLAT 1155/4885LMNA 774/4885 |
| US-20140072627-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | SLC35A1, SLC29A2, NEU2 | PLG 1107/4885PLAT 1155/4885LMNA 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.